More on OCGN

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (10.0 Score)

Upcoming Events

- Earnings (11/10/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Ocugen (NQ:OCGN)
Delayed: 1.06 +0.04 (3.92%)
Prev. Close $1.02  
Open$1.04 
52 Wk High$ 
52 Wk Low$ 
Day High$1.06 
Day Low$1.03 
P/E N/A  
EPS$ 
Volume1,449,144 


Sep 10, 2026 06:52 AM Ocugen, Inc. (OCGN) PT Lowered to $9.50 at H.C. Wainwright
Sep 1, 2026 07:02 AM Ocugen doses first patient in Phase 3 gene therapy trial for dry AMD
Sep 1, 2026 07:02 AM Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Aug 25, 2026 07:02 AM Ocugen to Participate in Upcoming September Investor and Industry Conferences
Aug 14, 2026 06:10 AM Form DEFA14A Ocugen, Inc.
Aug 13, 2026 12:42 PM Form SCHEDULE 13G/A Ocugen, Inc. Filed by: Janus Henderson Group Ltd.
Aug 7, 2026 10:29 AM Form SCHEDULE 13G Ocugen, Inc. Filed by: STATE STREET CORP
Aug 6, 2026 12:16 PM Form 10-Q Ocugen, Inc. For: Jun 30
Aug 6, 2026 08:31 AM Form 8-K Ocugen, Inc. For: Aug 06
Aug 6, 2026 07:53 AM Ocugen (OCGN) Misses Q2 EPS by 2c
View All Articles

Entities mentioned with OCGN

View All Entities